A landmark 2025 clinical trial has identified a surprisingly simple treatment that meaningfully reduces how long shingles patients suffer from post-viral nerve pain: low-dose valacyclovir, taken daily for twelve months. The Zoster Eye Disease Study, published in JAMA Ophthalmology in March 2025, found that patients who took 1,000 milligrams of valacyclovir per day experienced significantly shorter pain duration by eighteen months compared to those on placebo — and used substantially less neuropathic pain medication throughout. For the millions of older adults who develop shingles each year, many of whom already live with cognitive decline or dementia, this finding matters enormously. Prolonged pain disrupts sleep, accelerates cognitive deterioration, and makes caregiving harder for everyone involved.
But low-dose valacyclovir is only part of a shifting landscape. A novel drug called EMA401, tested across six countries, reduced chronic post-shingles pain by at least thirty percent in more than half of participants — with no serious side effects. Meanwhile, the Shingrix vaccine continues to prove itself as the single most effective tool for preventing postherpetic neuralgia altogether, with efficacy above ninety percent. And at the experimental edge, researchers at UCSF are implanting deep brain stimulation devices in patients whose pain has resisted every other intervention. This article walks through each of these developments, what they mean for people caring for aging loved ones, and the practical tradeoffs worth understanding before your next conversation with a doctor.
Table of Contents
- What Is the New Shingles Treatment That Reduces Post-Viral Pain Duration?
- How EMA401 Offers a Completely Different Approach to Post-Shingles Pain
- Why Prevention Still Outperforms Every Treatment — The Shingrix Evidence
- Comparing Antiviral Options — Valacyclovir, Acyclovir, and the Newer Alternatives
- The Hidden Risks of Pain Medication in Dementia Patients
- Deep Brain Stimulation and Magnetic Stimulation — Experimental Frontiers
- What the Next Few Years May Bring
- Conclusion
- Frequently Asked Questions
What Is the New Shingles Treatment That Reduces Post-Viral Pain Duration?
The treatment generating the most attention in 2025 is not a new molecule — it is a new way of using an old one. The Zoster Eye Disease Study, or ZEDS, was a randomized clinical trial conducted across ninety-five sites in the United States, Canada, and New Zealand. Between November 2017 and June 2024, researchers led by a team at NYU Langone Health enrolled 527 immunocompetent adults who had developed herpes zoster ophthalmicus, the form of shingles that strikes the eye and surrounding nerves. Half received two 500-milligram doses of valacyclovir daily — a total of 1,000 milligrams — for a full year. The other half received placebo. The primary endpoint, whether postherpetic neuralgia prevalence at twelve months differed between the two groups, was not met. At twelve months, thirty-eight percent of the valacyclovir group still had PHN compared to forty percent on placebo — a gap too small to be statistically significant.
But the secondary findings told a different story. By eighteen months, pain duration was significantly shorter in the treatment group, with a P value of .046. Neuropathic pain medication use was markedly lower as well: patients on valacyclovir averaged 271.4 milligrams per day of pain medication at twelve months compared to 363.4 milligrams per day in the placebo group, a difference that reached statistical significance at P equals .006. At eighteen months, the gap persisted — 209.0 milligrams versus 286.2 milligrams, P equals .01. In practical terms, that means fewer gabapentin side effects, less sedation, and more functional days for patients already navigating the challenges of aging. One detail worth flagging for caregivers: participants younger than sixty showed even better results, with lower pain scores at both twelve and eighteen months. this suggests that early, sustained antiviral therapy may be most effective when the immune system still has enough reserve to work alongside the drug. For older adults, especially those with dementia or other immunological vulnerabilities, the benefit may be more modest — but the reduction in pain medication use alone could meaningfully improve quality of life.
How EMA401 Offers a Completely Different Approach to Post-Shingles Pain
While the ZEDS trial refined the use of an existing antiviral, a separate line of research has pursued an entirely different strategy: blocking the pain pathway itself. EMA401, developed and studied by Professor Andrew Rice and his team at Imperial College London, targets a mechanism that no currently approved therapy addresses. In a trial involving 183 patients with postherpetic neuralgia across six countries, fifty-eight percent of those taking EMA401 reported that the drug was effective, with pain reductions of at least thirty percent. No serious side effects were documented during the study. That fifty-eight percent response rate deserves context. Existing first-line treatments for postherpetic neuralgia — drugs like gabapentin, pregabalin, and tricyclic antidepressants — help roughly a third to half of patients, and they come with well-documented problems. Gabapentin causes dizziness, drowsiness, and cognitive fog, effects that are especially dangerous for people already living with dementia or mild cognitive impairment.
Pregabalin carries similar risks plus the potential for dependence. If EMA401 can match or exceed those response rates without sedation or cognitive side effects, it could become a critical option for the very population that tolerates existing drugs the worst. However, there is a significant caveat. EMA401 has not yet received regulatory approval, and larger confirmatory trials are still needed before it reaches pharmacy shelves. Researchers at Imperial College believe the drug may also prove effective against neuropathic pain caused by diabetes, HIV, nerve injury, and chemotherapy — which would expand its market and potentially accelerate its development timeline. But for now, it remains an investigational compound. Families managing shingles pain in a loved one with dementia should know it exists and ask their neurologist about trial eligibility, but they should not count on it being available in the near term.
Why Prevention Still Outperforms Every Treatment — The Shingrix Evidence
For all the progress in treating postherpetic neuralgia, the most effective intervention remains preventing it from developing in the first place. Shingrix, the recombinant zoster vaccine manufactured by GSK, is ninety-one percent effective at preventing postherpetic neuralgia in adults fifty and older and eighty-nine percent effective in adults seventy and older. Protection remains above eighty-five percent for at least four years, and in adults over seventy, immunity stays high for at least seven years. The World Health Organization’s 2025 recommendations endorse Shingrix as the preferred option for preventing both shingles and PHN, including for immunocompromised individuals — a group that now explicitly includes many dementia patients on immunosuppressive therapies. Consider a specific scenario that plays out in memory care facilities every winter. An eighty-two-year-old woman with moderate Alzheimer’s disease develops a shingles rash on her torso. She cannot reliably describe her pain, so caregivers notice it only when she begins refusing food, sleeping poorly, and becoming more agitated.
By the time antiviral therapy starts, the seventy-two-hour window for maximum effectiveness has already closed. She develops postherpetic neuralgia that persists for months, accelerating her cognitive decline and requiring sedating pain medications that further cloud her thinking. Had she received two doses of Shingrix before her diagnosis progressed, the odds of this entire cascade would have dropped by more than ninety percent. The barrier, unfortunately, is often logistical rather than medical. Many older adults with dementia fall out of routine preventive care. Their caregivers are managing so many immediate crises that a two-dose vaccine series slips through the cracks. If you are caring for someone with early-stage cognitive impairment, getting Shingrix on the calendar now — before the diagnosis becomes all-consuming — is one of the highest-impact preventive steps available.
Comparing Antiviral Options — Valacyclovir, Acyclovir, and the Newer Alternatives
Three antivirals are currently FDA-approved for treating acute shingles: acyclovir, famciclovir, and valacyclovir. They are not interchangeable, and the differences matter. In head-to-head comparisons, valacyclovir resolves shingles-related pain faster than acyclovir — a median of thirty-eight days versus fifty-one days when treatment begins within seventy-two hours of rash onset. That thirteen-day difference is not trivial for a patient in severe pain, and it is especially relevant for dementia patients whose behavioral symptoms worsen with every additional day of uncontrolled discomfort. Valacyclovir also has a practical dosing advantage.
It requires fewer daily doses than acyclovir, which improves adherence — a critical factor when the patient has cognitive impairment and depends on a caregiver to administer medication on schedule. Famciclovir falls somewhere in between and is sometimes preferred for patients with renal concerns, though it lacks the robust comparative data that valacyclovir has accumulated. A newer antiviral called amenamevir, which works through a different mechanism as a helicase-primase inhibitor, has shown comparable efficacy to valacyclovir in treating acute shingles. However, it has not demonstrated a significant advantage in preventing postherpetic neuralgia. For caregivers weighing options with a physician, the current evidence still favors valacyclovir as the first-line antiviral for shingles — and the ZEDS trial now provides a rationale for continuing it at a low dose well beyond the standard seven-to-ten-day acute treatment course.
The Hidden Risks of Pain Medication in Dementia Patients
A 2025 study published in the journal Medicine compared pharmacologic and non-pharmacologic approaches to postherpetic neuralgia treatment in sixty patients over twenty-four months. The drug-based treatments reduced pain more effectively at twelve months — but they came with a cost. Dizziness affected 16.7 percent of patients receiving pharmacologic treatment, and sleepiness affected 10.0 percent. The study’s authors recommended combining both approaches to balance pain relief against side effects. For dementia patients, those side effect rates are not just inconveniences — they are genuine dangers.
Dizziness increases fall risk, and falls are among the leading causes of hospitalization and accelerated decline in people with Alzheimer’s and related dementias. Sleepiness compounds existing cognitive impairment, making it harder to engage in the social interaction and physical activity that slow disease progression. A caregiver who sees their loved one becoming more confused or unsteady after starting gabapentin for shingles pain may assume the dementia is worsening, when in reality the culprit is the pain medication itself. This is precisely why the ZEDS trial’s finding on reduced pain medication use is so significant for the dementia care community. If twelve months of low-dose valacyclovir can cut neuropathic pain medication use by roughly a quarter — as the trial data suggest — the downstream benefits extend far beyond pain relief. Fewer falls, less sedation, better sleep quality, and more preserved cognitive function during a period that is already brutally difficult for patients and families alike.
Deep Brain Stimulation and Magnetic Stimulation — Experimental Frontiers
For the small but devastating subset of patients whose postherpetic neuralgia resists every available treatment, researchers at the University of California, San Francisco are testing interventions that bypass the peripheral nervous system entirely. Current clinical trials at UCSF include implanted deep brain stimulation devices that target multiple brain regions involved in chronic pain processing. These are not theoretical proposals — they are active studies enrolling patients with treatment-resistant pain, including PHN.
Alongside the implantable devices, UCSF is also trialing noninvasive magnetic stimulation for neuropathic pain. This approach uses targeted magnetic fields to modulate brain activity without surgery, offering a potential option for patients who cannot tolerate or do not want an implant. Both technologies are still in the trial phase and not yet available as standard treatments. But for families managing a loved one with both dementia and intractable post-shingles pain — a combination that can make life genuinely unbearable for patient and caregiver alike — knowing that these trials exist and that referral is possible can itself be a form of relief.
What the Next Few Years May Bring
The convergence of multiple research threads — long-term low-dose antivirals, novel pain-pathway drugs like EMA401, improved vaccination uptake, and neurostimulation technologies — suggests that postherpetic neuralgia management is entering a genuinely different era. The ZEDS trial alone may change clinical practice within the next year or two, as physicians begin prescribing extended valacyclovir courses for high-risk patients rather than limiting treatment to the acute phase.
For the dementia care community specifically, the most important shift may be attitudinal. Shingles pain in cognitively impaired patients has historically been undertreated because the patients cannot advocate for themselves and because the available medications create their own cognitive problems. As lower-risk treatment options become validated and prevention rates climb with broader Shingrix adoption, there is real reason to expect that fewer dementia patients will endure the prolonged, unnecessary suffering that post-shingles pain has inflicted for decades.
Conclusion
The evidence published in 2025 confirms that the landscape of shingles pain management is changing in meaningful ways. Low-dose valacyclovir taken over twelve months reduces pain duration and cuts neuropathic medication use by a clinically significant margin. EMA401 offers a novel mechanism with a strong early efficacy signal and minimal side effects. Shingrix remains over ninety percent effective at preventing the problem altogether. And for the most refractory cases, neurostimulation research at major academic centers is pushing into territory that would have seemed implausible a decade ago.
For caregivers of people with dementia, the practical takeaway is threefold. First, ensure your loved one has received the Shingrix vaccine before cognitive decline makes preventive care harder to coordinate. Second, if shingles does occur, push for valacyclovir over acyclovir and discuss extended low-dose treatment with the prescribing physician. Third, monitor pain medication side effects aggressively — dizziness, sedation, and confusion from gabapentin or pregabalin can mimic or worsen dementia symptoms, and the new evidence suggests there are paths to reducing those drug burdens. The goal is not just less pain, but better-preserved function during a stage of life where every clear-headed day counts.
Frequently Asked Questions
Can someone with dementia safely receive the Shingrix vaccine?
Yes. Shingrix is a recombinant vaccine, not a live virus, and the 2025 WHO recommendations explicitly include immunocompromised individuals. Dementia itself is not a contraindication. The main challenge is logistical — ensuring the second dose is administered two to six months after the first.
How long after a shingles rash appears should antiviral treatment start?
Within seventy-two hours of rash onset for maximum benefit. Valacyclovir started in that window resolves pain in a median of thirty-eight days versus fifty-one days for acyclovir. For dementia patients who cannot report symptoms clearly, caregivers should watch for unexplained agitation, skin sensitivity, or localized rash and seek medical evaluation promptly.
Does the ZEDS trial apply to all types of shingles, or only eye-related cases?
The ZEDS trial specifically enrolled patients with herpes zoster ophthalmicus, the form affecting the eye. Whether the pain-duration benefits of extended low-dose valacyclovir apply to shingles in other locations has not yet been tested in a comparable trial. However, the biological rationale — suppressing low-level viral reactivation over time — is not specific to the eye, and many clinicians expect the findings to generalize.
What makes EMA401 different from existing pain medications for shingles?
EMA401 targets a pain-signaling mechanism that no currently approved drug addresses. Unlike gabapentin and pregabalin, which work by dampening nerve signaling broadly and cause sedation, EMA401 produced no serious side effects in its trial of 183 patients. It is not yet FDA-approved and remains investigational.
Is deep brain stimulation a realistic option for older adults with post-shingles pain?
Currently, it is available only through clinical trials, primarily at UCSF, and is reserved for patients with treatment-resistant chronic pain. The implantation surgery carries risks that must be weighed carefully, especially in older adults with multiple health conditions. Noninvasive magnetic stimulation trials at the same institution may offer a lower-risk alternative for eligible patients.
